Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Bacterial Populations Rapidly Evolve a Time-linked Tolerance to Antibiotics

By BiotechDaily International staff writers
Posted on 14 Jul 2014
A team of molecular microbiologists has found that some types of bacteria develop tolerance towards antibiotic treatment by "learning" how to time the length of exposure to the drug and evolving an extended period of dormancy that protects the organisms from the effects of the antibiotic.

Investigators at the Hebrew University of Jerusalem (Israel) followed the evolution of bacterial populations under intermittent exposure to the high concentrations of antibiotics used in the clinic and characterized the evolved strains in terms of both resistance (growth of microorganisms in the constant presence of an antibiotic, provided that the concentration of the antibiotic is not too high) and tolerance (survival of microorganisms during antibiotic treatment, even at high antibiotic concentrations, as long as the duration of the treatment is limited).

Initially bacterial populations were treated with antibiotics for three hours each day. Exposure times were later increased to five and eight hours per day.

By monitoring the phenotypic changes at the population and single-cell levels, the investigators found that after only 10 days the first adaptive change to antibiotic stress became apparent. This was the development of tolerance towards the antibiotic through a major adjustment in the single-cell lag-time distribution, without a change in resistance. They also found that the lag time of bacteria before regrowth was optimized to match the duration of the antibiotic-exposure interval. All bacterial strains adapted by specific genetic mutations, which became fixed in the evolved populations.

The investigators also reported that whole genome sequencing of the evolved strains and restoration of the wild-type alleles allowed the identification of target genes involved in this antibiotic-driven phenotype, which they called "tolerance by lag" (tbl).

The results of this study, which was published in the June 25, 2014, online edition of the journal Nature, demonstrated that bacteria can evolve within days. The investigators expect that better understanding of lag-time evolution as a key determinant of the survival of bacterial populations under high antibiotic concentrations will lead to new approaches to preventing the evolution of antibiotic resistance.

Related Links:

Hebrew University of Jerusalem



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Lab Technologies

view channel

Genome-Wide Mutation-Searching Computational Software Designed for Genomic Medicine

Analysis software cross-references a patient’s symptoms with his genome sequence to help physicians in the diagnosis of disease. This software was created by a team of scientists from A*STAR’s Genome Institute of Singapore (GIS), led by Dr. Pauline Ng. The research findings were published August 3, 2014, in the journal... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.